January 28, 2022 10:13 AM ESTUpdated 01:46 PM
R&D
FDA+

Up­dat­ed: JAK woes con­tin­ue as Eli Lil­ly warns of pos­si­ble Olu­mi­ant CRL for atopic der­mati­tis and re­ports PhI­II fail in lu­pus

Max Gelman

Senior Editor

Eli Lil­ly and In­cyte have plans to turn their block­buster Olu­mi­ant drug in­to a megablock­buster. But those plans ran in­to a ma­jor road­block Fri­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times